title: Epirubicin and cisplatin in recurrent, metastatic or advanced carcinoma of the cervix.
abstract: The purpose of this study is to determine the efficacy of combination chemotherapy using Cisplatin and Epirubicin in carcinoma of the cervix. Fifty-six patients with local recurrent and/or metastatic carcinoma of the cervix have been treated using Cisplatin 60 mg/m2 and Epirubicin 90-100 mg/m2 every three weeks. The overall response rate was 67.9% (CR 14.3%, PR 53.6%). The response rate was higher in a previously non-treated metastatic area (PR+CR = 93.7%). Four out of fourteen patients in stage IVB had long-term survival ranging from 14 to 85 months. The toxicity was moderate. Leukocytopenia grade IV occurred in 20%. The combination is effective in carcinoma of the cervix, especially in previously non-treated patients.
authors.affiliation: Section of Radiation Oncology, Faculty of Medicine, Chiangmai University, Thailand.
authors.forename: V
authors.initials: V
authors.lastname: Lorvidhaya
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D002945:Cisplatin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D015996:Survival Rate; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary
chemical_list: D015251:Epirubicin; D002945:Cisplatin